Singlobet Ltd

http://www.singlogen.com

Nottingham, Nottinghamshire, United Kingdom
Watch the video Watch the video

  • Clean Water, Sanitation and Hygiene

  • China | India | South Africa | Global Programs

  • Economically disadvantaged people

  • Business

  • ---

  • ---

Executive Summary

SinglotexTM is a phthalocyanine that is water soluble during activation only which occurs only in the presence of UV light. The reaction creates singlet oxygen, which is inexhaustible, so offers a long term solution to eradicate pollution and pathogens. Singlet oxygen is a naturally occurring aggressive chemical species that very rapidly reacts with any nearby biomolecules. Science has yet to discover an anaerobic disease, infectious or putrefying bacteria that Singlet Oxygen does not kill so it has huge potential in assisting the managing pollution and disease. The 100&Change fund would enable Singlobet and it's research partners to review the potential use of singlotex to treat disease, specifically develop clinical methodology for treating cancer and bloodborne diseases, like HIV and Zyka. Accelerate current research on how we may utilise infrastructure to reduce air pollution (NO) Treat dangerous algae and pathogens in water Treat unsanitary drinking water so it is pathogen free

Watch the video

The Problem

We want to research, test and licence the use of SingloTex technology to create affordable treatment options for controlling disease, cleaning water and treating pollution the impact of which make it difficult for low income countries to develop and advance. We know 663m people lack access to clean water which results in preventable disease and death. World Health Organisation statistics show that infectious and parasitic disease is one of the main causes of years lost due to disabilities for 10-24 year olds and that HIV, amongst other blood borne diseases, continues to be a major global public health issue. Add to this the damage air pollution and toxic algae cause in industrialised areas and it is quite clear that globally we are further negatively affecting human health and well being. This is exacerbated by inequality in terms of access to healthcare (geography and cost), lack of sanitation and pollution control particularly in low income countries. Pollution and disease also affect the ecosystem which humans rely on, for example for food and livelihood. In low income countries, investment in healthcare is low with slow/no growth which means that healthcare innovation is not only affordable, but that it utilises existing infrastructure and if possible creates local jobs and hence economic development. We believe we have a potential solution that could be researched and tested rapidly. It will utilise existing infrastructure and create jobs through setting up research, manufacturing and treatment opportunities in low income countries, addressing not only disease and pollution but economic development.

Proposed Solution

SingloTex is a patented phthalocyanine dye. It readily transfers to multiple materials and does not wash out. Through catalytic reaction (ie the reaction is inexhaustible) SingloTex undergoes a photodynamic reaction with UV light to produce highly reactive oxygen species that since phthalocyanines were discovered in the 1920's, have been known to kill pathogens and deoxygenated single cell species, like algae. SingloTex is the only known phthalocyanine that is temporarily water soluble, so offers a safe means of healthcare and sanitation use - other phthalocyanines and photodynamic materials require solvents and other more complex methods of deployment which can be harmful. Based on this https://www.sheffield.ac.uk/news/nr/catalytic flags bust pollution in petrol stations 1.447219 we know singlet oxygen will remove NO from the atmosphere, but TiO2 has limited use because it washes out of clothing. SingloTex could be painted onto the surface of existing infrastructure and buildings or put into outer clothing and, with research, including it in the exhaust system of vehicles, SingloTex to produce an enhanced outcome. We will create a certified food safe medium through which water would be filtered to kill pathogens to make water safe to drink, presenting an inexhaustible, affordable process that will work even in the remotest parts of the world where there is UV light present. Through collaboration with technology providers, we will research and test in vitro and in vivo the use of SingloTex for all of these applications, gain appropriate licences for its use and build new manufacturing facilities where the technology is most needed.

Evidence of Effectiveness

[1]Photodynamic therapy (PDT) is a revolutionary medical technology that uses lasers to activate light sensitive dyes to diseases in a non surgical, minimally invasive way. PDT has been approved by regulatory agencies around the world (including the U.S. Food and Drug Administration) in response to growing demand for less debilitating, safer and more effective cancer treatments. However, insolubility in water has long been considered a limitation of this class of dyes. SinglotexTM gets around these problems with a unique chemistry. As the dye deposits it changes from being water soluble to lipid soluble which allow passive uptake into the tumour and apoptotic cell death pathway. This improved deposition of the dye leads to prolonged singlet oxygen generation and far more efficient destruction of the diseased tissue. Singlet oxygen has significant anti microbial potency.[2] Our work with the Environment Agency has demonstrated that SinglotexTM in a concentration of around 1:100 concentration, sprayed over an area of 20m2 killed blanket algae in 4 weeks with no adverse impact on the 30,000 fry in the pond. We have treated aquarium water and ponds which has resulted in algae control, fish adding weight over the winter and increased breeding. Our tests have shown that in terms of kill rate, SinglotexTM has achieved log 4 6 (log 6 is the NHS standard for decontamination). [1] http://www.nhs.uk/Conditions/photodynamic therapy NGPDT sonodynamic therapy/Pages/Introduction.aspx http://www.colorantshistory.org/PhthaloDiscovery.html http://www.chm.bris.ac.uk/motm/phthalocyanine/pbpc.html http://www.worldscientific.com/doi/pdf/10.1142/S108842461650070X?src=recsys [2] https://www.ncbi.nlm.nih.gov/pubmed/25155698 http://www.bibliotecapleyades.net/ciencia/supressed_inventions/suppressed_inventions08.htm

Previous Performance

We plan to build an extensive expert team through our relationships with universities and healthcare providers globally, so we do not plan to do this on our own because the projects are too complex and need independent analysis and research for the outcomes to be credible. The experts we are currently working with including the NHS, Universities University of Central Lancashire, Exeter, Leicester and Brunel the Environment Agency, Sintef and DHI will continue to be independent researchers working with us. Through these existing collaborators, we will identify and add medical and biotechnology technology providers, additional universities and healthcare establishments in low income countries so that they are part of the vehicle that carries out the independent research can undertake in vitroand in vivo trails, including clinical trials to develop the expertise in deploying the technology. Our team is highly competent multidisciplinary team of chemists, engineers and sustainability, biomedical and marketing/communication experts and will be involved in the research as part of the panel each director will map to a specific research panel, taking the lead for Singlobet in that specific research topic based on their exisiting expertise Guy will lead on aquaculture, Darren will lead on healthcare, Phil will lead on drinking water and Diane will lead on air pollution (NO reduction) each Singlobet lead will be responsible for feeding back to the board on the progress of the research, enlisting help from Barry, Peter and Adam as appropriate.

The Team

Team Purpose

Singlobet has one overarching and realistic vision: To contribute to a healthier, greener and cleaner world through the maximizing the use of its products including the unique SingloTex dye technology. It is a vision underscored by one common denominator: Advancement in human and animal health and well being and reduction of environmental pollution through the eradication of even the most antibiotic resistant bacteria, potentially fatal viruses and fungal infections. Our ethos is based on ethics the poorest amongst us should have equal rights to access, amongst other things, sanitary water and clean living conditions and healthcare. We know our technology will reduce the cost of healthcare because the reliance on expensive and often toxic pharmaceuticals for the treatment of multiple diseases with be severed, which means increased accessibility and improved quality of life for millions of people. We also plan to build manufacturing facilities across the globe; creating multiple skilled local workers.

Team Structure

Singlobet is an Anglo American business employing a seven strong multidisciplinary team (see attachment) of chemists, engineers and sustainability, biomedical and marketing/communication experts. To enable good communication across time zones, we carry out manufacturing and run our day to day operations from Nottingham and operate a virtual office holding twice weekly board meeting video conferences. Key partners join our conferences so that all board members can contribute and provide direction as may be needed to our projects. Chief executive officer, Guy Eatch, is supported day to day by Diane Booth to further develop our business plan and strategic proposition, identify potential research opportunities and partners. Collectively with some 225 years' experience in our respective fields, we all lever relationships/networks and technical capabilities to engage with potential partners, research establishments and clients to develop the research opportunities. We have small research projects ongoing at present, led by specific team members, including collaboration with a crowd funding organisation; photodynamic therapy cancer treatment trial with the NHS in Cumbria; research with the Environment Agency and fisheries in the treatment of algae and pathogens that cause fish mortality; and research with TeamSky to review how SingloTexTM could help to prevent team illness. Funds would accelerate the spread of benefits from SingloTex